Artivion, Inc. (AORT) Stock Price & Analysis
Artivion, Inc. (AORT) closed at USD 21.87 on Thursday, October 15, 2026, up 1.58% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 21.53; the Oct 15, 2026 session ranged USD 21.53–22.49 on volume of 512,463 shares. Market capitalization is $1.07B, with a 52-week range of USD 19.16–48.25 (NYQ). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AORT.md
Key facts (AORT)
- 1 of 80 tracked superinvestors hold AORT (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.75 on a 1–5 scale) (8 analysts), mean target USD 42.15 (range 38–48).
- Total return with dividends: 1Y -47.4% vs S&P 500 +18.1%; 5Y +2.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD 0.07, revenue estimate $121M.
Superinvestors (SEC 13F-HR, Q2 2026) (AORT)
1 of 80 tracked investors hold AORT. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.01% | $7.8M | Added +11.2% |
Analysts (AORT)
Consensus Buy (mean 1.75 on a 1–5 scale), 8 analysts; mean target USD 42.15 (low 38, high 48).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-18 | Canaccord Genuity | Target raised | Buy | $39 → $40 |
| 2026-07-20 | Needham | Reiterated | Buy | $44 |
Total return (dividends reinvested) (AORT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -47.4% | +2.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -47.5% | +0.5% |
| Volatility (annualized) | 51.6% | 50.0% |
| Max drawdown | -57.8% (Nov 2025→Jun 2026) | -56.9% (Nov 2025→Jun 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 21.87 |
|---|---|
| Change | ▲ 1.58% (up) |
| Previous Close | USD 21.53 |
| Open | USD 22.02 |
| Day Range | USD 21.53 – 22.49 |
| 52-Week Range | USD 19.16 – 48.25 |
| Volume | 512,463 shares |
| Market Cap | $1.07B |
| Exchange | NYQ |
Technical Analysis (AORT)
Nexqual's technical model rates AORT "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.86 (neutral) |
| vs SMA50 | Below (USD 25) |
| MACD | -0.94 (negative) |
Analyst Ratings (AORT)
Wall Street analysts rate AORT "Buy" based on 8 analysts, with a mean price target of USD 42.15 (range USD 38–48), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 42.15 |
| High Target | USD 48 |
| Low Target | USD 38 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (AORT)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 0.07 |
| Revenue Estimate | $120.93M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.13 vs est 0.1 ▲ beat |
| 2026-03-31 | USD 0.08 vs est 0.12 ▼ miss |
| 2025-12-31 | USD 0.17 vs est 0.18 ▼ miss |
| 2025-09-30 | USD 0.16 vs est 0.15 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (AORT)
| Total Revenue | $471.47M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +11.30% |
| Gross Margin | +64.37% |
| Operating Margin | +9.01% |
| Profit Margin | -0.67% |
| ROE | -0.73% |
| Debt / Equity | 0.92 |
| Current Ratio | 3.47 |
| Total Cash | $77.32M |
| Total Debt | $407.97M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $839,000 (0.2% of revenue) |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (AORT)
Nexqual rates Artivion, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 64%, operating 9% |
| Balance Sheet | Mixed — $77M cash vs $408M debt |
| Cash Flow | Mixed — FCF $839K (FY ended Dec 2025, 10-K), slim 0.2% margin |
| Efficiency | Critical — ROE -1%, ROA 2.6% |
Ownership (AORT)
| Insider Ownership | +4.29% |
|---|---|
| Institutional Ownership | +96.40% |
| Shares Outstanding | 48.76M |
| Float | 46.28M |
| Short % of Float | +8.92% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (AORT)
Artivion, Inc. is led by James Patrick Mackin (age 58), Chairman, President & CEO, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Chairman, President & CEO | James Patrick Mackin (age 58) |
|---|---|
| EVP, COO, CFO & Treasurer | Lance A. Berry (age 53) |
| Senior VP and Chief Strategy & Digital Officer | Jason D. Asper (age 49) |
| Senior Vice President of Regulatory & Quality | Andrew M. Green (age 56) |
| Senior Vice President of Clinical Research & Chief Medical Officer | Simona Zannetti |
Major Backers & Investors (AORT)
Notable institutional backers of Artivion, Inc. include Nomura Asset Management International Inc, Morgan Stanley, Fidelity, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nomura Asset Management International Inc | 6.53% |
| Morgan Stanley | 5.25% |
| Fidelity | 4.41% |
| Juniper Investment Company, LLC | 4.14% |
| FMR, LLC | 4.03% |
| Ophir Asset Management Pty Ltd | 3.69% |
| Perceptive Advisors Llc | 3.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 21.42% |
| Vanguard Group | 7.11% |
| State Street | 3.81% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc | USD 61.36 | ▲ 4.98% |
| ALMR | Alamar Biosciences, Inc. | USD 27.42 | ▲ 16.58% |
| INSP | Inspire Medical Systems, Inc. | USD 70.12 | ▲ 1.83% |
| BFLY | Butterfly Network, Inc. | USD 7.85 | ▼ 3.09% |
| AXGN | AxoGen, Inc. | USD 35.63 | ▼ 1.49% |
| UFPT | UFP Technologies, Inc. | USD 297.19 | ▲ 0.99% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt